secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001493152-25-020816
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg
------------------------------------------------------------------------------

- October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.
- Medical practices with multiple CyPath orders rose 106% QoQ in Q3 and 67% in Oct vs YTD monthly avg.
- CyPath Lung noninvasive sputum test uses AI/flow cytometry; clinical study showed 92% sensitivity, 87% specificity.
- CEO Maria Zannes cites growing physician trust and successful outreach to pulmonologists, health systems, VA centers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225020816/0001493152-25-020816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225020816/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-020816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer